Emerging retatrutide, a combined-action drug targeting equally GLP-1 and GIP receptors, is creating considerable buzz within the healthcare community. Initial clinical trials have shown substantial reductions in body weight and gains in physiological markers for individuals with overweight. Experts believe this ground-breaking approach has the pote